Eli Lilly and Company Stock News

What should investors do when stocks are tanking over the short term? Probably the best answer is to think long term.

The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out weight-loss drugs. Eli Lilly stock skidded.

President Donald Trump dropped a Biden administration proposal to have Medicare cover obesity drugs, including popular GLP-1 treatments such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound. But the Centers for Medicare and Medicaid Services said it may reconsider coverage of those drugs in the future, according to a fact sheet on the rule.

Sangamo Therapeutics, Inc.'s deal with Eli Lilly to develop genomic medicines for CNS using the STAC-BBB AAV capsid brings in an $18M upfront payment and the potential to earn $1.4B in milestone payments. The Fabry Disease gene therapy program, with phase 1/2 STAAR study data expected in 1H 2025, is a major near-term catalyst for investors to keep an eye on. Positive eGFR slope data could lead ...

1 Ideal Buy From 23 "Safer" April Dividend Dogs In 50 Fortune World's Most Admired Companies (FWMAC)

These 5 companies will have minimal impact from the tariffs and could deliver strong results in 2025.

Eli Lilly (LLY -2.70%) is the most valuable healthcare company in the world, worth more than $700 billion. Over the past 12 months, however, the stock's performance has been fairly lackluster, rising by just around 6%.

Tobacco giant Altria (MO -1.77%) provides a tremendously high dividend yield of 7%, which is well above the S&P 500 index average of 1.3%. But it comes with risks, as its business has been struggling to grow in recent years, and its rate of dividend increases has been modest.